Ser1852

Site Information
PPtsRKRsRsRtsPA SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 4753731

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 )
Disease tissue studied:	breast cancer ( 2 ) , leukemia ( 3 ) , acute myelogenous leukemia ( 3 ) , lung cancer ( 2 , 9 ) , non-small cell lung cancer ( 2 ) , non-small cell lung adenocarcinoma ( 9 )
Relevant cell line - cell type - tissue:	293 (epithelial) [AT1 (human), transfection, AT1R stable transfected HEK293] ( 7 ) , BT-20 (breast cell) ( 2 ) , BT-549 (breast cell) ( 2 ) , GM00130 (B lymphocyte) ( 8 ) , H2077 (pulmonary) ( 2 ) , H322M (pulmonary) ( 2 ) , HCC1359 (pulmonary) ( 2 ) , HCC2279 (pulmonary) ( 2 ) , HCC366 (pulmonary) ( 2 ) , HCC4006 (pulmonary) ( 2 ) , HCC78 (pulmonary) ( 2 ) , HeLa (cervical) ( 1 , 5 ) , Jurkat (T lymphocyte) ( 4 , 6 ) , KG-1 (myeloid) ( 3 ) , MDA-MB-231 (breast cell) ( 2 ) , MDA-MB-468 (breast cell) ( 2 ) , NCI-H157 (pulmonary) ( 2 ) , NCI-H1666 (pulmonary) ( 2 ) , NCI-H2172 (pulmonary) ( 2 ) , NCI-H3255 (pulmonary) ( 9 , 10 ) , NCI-H520 (squamous) ( 2 ) , PC9 (pulmonary) ( 2 )

References
1	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
2	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
3	Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56 22115753 Curated Info
4	Guo A (2011) CST Curation Set: 11987; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]XP Curated Info
5	Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5 21712546 Curated Info
6	Possemato A (2010) CST Curation Set: 10730; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (81E12B5) Rabbit mAb Cat#: 10003 Curated Info
7	Christensen GL, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9, 1540-53 20363803 Curated Info
8	Bennetzen MV, et al. (2010) Site-specific phosphorylation dynamics of the nuclear proteome during the DNA damage response. Mol Cell Proteomics 9, 1314-23 20164059 Curated Info
9	Moritz A, et al. (2010) Akt-RSK-S6 Kinase Signaling Networks Activated by Oncogenic Receptor Tyrosine Kinases. Sci Signal 3, ra64 20736484 Curated Info
10	Moritz A (2008) CST Curation Set: 5654; Year: 2008; Biosample/Treatment: cell line, NCI-H3255/Iressa; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS/T) Immunoaffinity Beads Cat#: 1979 Curated Info